Studylog has been featured in such publications as the following:

Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers

Deborah F. Wilsker, Allison M. Barrett, Angie B. Dull, etc. Clin Cancer Res. 2019 May 15; 25(10): 3084–3095.


MDM2 and MDM4 are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors

Thomas P. Howard, Taylor E. Arnoff, Melinda R. Song, etc. Cancer Res. 2019 May 1; 79(9): 2404–2414.


Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma

Elizabeth C. Randall, Kristina B. Emdal, Janice K. Laramy, etc. Nat Commun. 2018; 9: 4904.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Olga Kondrashova, Monique Topp, Ksenija Nesic, etc. Nat Commun. 2018; 9: 3970.

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models

Anna Capasso, Todd M. Pitts, Peter J. Klauck, etc. Anticancer Drugs. 2018 Oct; 29(9): 827–838.


Reactive astrocytic S1P3 signaling modulates the blood–tumor barrier in brain metastases

Brunilde Gril, Anurag N. Paranjape, Stephan Woditschka, etc. Nat Commun. 2018; 9: 2705.


Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity

S. W. Fanning, L. Hodges-Gallagher, D. C. Myles, etc. Nat Commun. 2018; 9: 2368.


MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis

Arnab Ghosh, Sandipto Sarkar, Snigdha Banerjee, etc. PLoS One. 2018; 13(5): e0198143.


Novel fluoroindenoisoquinoline non-camptothecin topoisomerase I inhibitors

Laetitia Marzi, Keli Agama, Junko Murai, etc. Mol Cancer Ther. 2018 Aug; 17(8): 1694–1704.


Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

Stephen J. Pettitt, Dragomir B. Krastev, Inger Brandsma, etc. Nat Commun. 2018; 9: 1849.

Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors

Apurva K. Srivastava, Melinda G. Hollingshead, Jeevan P. Govindharajulu, etc. Mol Cancer Ther. 2018 Mar; 17(3): 698–709.

ALK inhibitor response in melanomas expressing EML4-ALK fusions and alternate ALK isoforms

Kasey L. Couts, Judson Bemis, Jacqueline A. Turner, etc. Mol Cancer Ther. 2018 Jan; 17(1): 222–231.

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer

Matthew P. Goetz, Krishna R. Kalari, Vera J. Suman, etc. J Natl Cancer Inst. 2017 Jul; 109(7): djw306.

Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay

Jiuping Ji,1, Yiping Zhang, Christophe E. Redon, etc. PLoS One. 2017; 12(2): e0171582.

Analysis and Implementation of an Electronic Laboratory Notebook in a Biomedical Research Institute

Santiago Guerrero, Gwendal Dujardin, Alejandro Cabrera-Andrade, etc. PLoS One. 2016; 11(8): e0160428.